Literature DB >> 31169896

Survivorship Bias in Analyses of Immune Checkpoint Inhibitor Trials.

Sarah C Conner1, Ludovic Trinquart1.   

Abstract

Entities:  

Year:  2019        PMID： 31169896      PMCID： PMC8974512          DOI： 10.1001/jamaoncol.2019.1187

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  4 in total

1.  Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables.

Authors:  James R Anderson; Kevin C Cain; Richard D Gelber
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

Review 2.  Landmark analysis at the 25-year landmark point.

Authors:  Urania Dafni
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-05

3.  Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.

Authors:  Yukihiro Toi; Shunichi Sugawara; Jun Sugisaka; Hirotaka Ono; Yosuke Kawashima; Tomoiki Aiba; Sachiko Kawana; Ryohei Saito; Mari Aso; Kyoji Tsurumi; Kana Suzuki; Hisashi Shimizu; Yutaka Domeki; Keisuke Terayama; Atsushi Nakamura; Shinsuke Yamanda; Yuichiro Kimura; Yoshihiro Honda
Journal:  JAMA Oncol       Date:  2019-03-01       Impact factor: 31.777

4.  Analysis of survival by tumor response.

Authors:  J R Anderson; K C Cain; R D Gelber
Journal:  J Clin Oncol       Date:  1983-11       Impact factor: 44.544
  4 in total
  5 in total

1.  Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study.

Authors:  Philippe Thuillier; Claire Joly; Zarrin Alavi; Geneviève Crouzeix; Renaud Descourt; Gilles Quere; Véronique Kerlan; Nathalie Roudaut
Journal:  Cancer Immunol Immunother       Date:  2021-01-09       Impact factor: 6.968

2.  Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.

Authors:  Federico Nichetti; Francesca Ligorio; Emma Zattarin; Diego Signorelli; Arsela Prelaj; Claudia Proto; Giulia Galli; Antonio Marra; Giulia Apollonio; Luca Porcu; Filippo de Braud; Giuseppe Lo Russo; Roberto Ferrara; Marina Chiara Garassino
Journal:  Cancers (Basel)       Date:  2019-12-25       Impact factor: 6.639

Review 3.  A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.

Authors:  Neeraj Chhabra; Joseph Kennedy
Journal:  J Med Toxicol       Date:  2021-04-07

4.  Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort.

Authors:  Angelica D'Aiello; Juan Lin; Rasim Gucalp; Vafa Tabatabaie; Haiying Cheng; Noah A Bloomgarden; Yaron Tomer; Balazs Halmos
Journal:  Cancers (Basel)       Date:  2021-03-23       Impact factor: 6.639

5.  Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events.

Authors:  Jessica M Logan; Doug A Brooks; Andrew Rowland; Michael J Sorich; Ashley M Hopkins
Journal:  J Oncol       Date:  2021-06-16       Impact factor: 4.375
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.